1 / 1

JAK2

Stat5 Inhibitors in Prostate Cancer Therapy Development. Prl. PrlR Antagonists. pY. pY. pY. pY. pY. pY. pY. pY. pY. pY. pY. pY. pY. pY. Jak2 Inhibitors. JAK2. JAK2. PrlR. PrlR. EGFR1. ErbB2. Src. HSP. AR. Stat5 Inhibitors. DHT. DHT. DHT. DHT. DHT. DHT. DHT.

sarai
Download Presentation

JAK2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stat5 Inhibitors in Prostate Cancer Therapy Development Prl PrlR Antagonists pY pY pY pY pY pY pY pY pY pY pY pY pY pY Jak2 Inhibitors JAK2 JAK2 PrlR PrlR EGFR1 ErbB2 Src HSP AR Stat5 Inhibitors DHT DHT DHT DHT DHT DHT DHT DHT DHT DHT DHT STAT5 A/B STAT5 A/B Stat5-induced stability of AR HSP High nuclear Stat5 predicts PCa recurrence and PCa-specific death. • Stat5 Locus Amplification: 20-30% of advanced PCas • Constitutively Active Kinase Pathways AR STAT5 A/B STAT5 A/B AR AR AR AR AR AR Stat5 inhibition induces apoptosis of PCa cells and inhibits PCa tumor growth. STAT5 A/B STAT5 A/B BCL-XL, Cyclin D1 AR-independent effects of Stat5 on PCa cell viability Survival PSA Growth STAT5 A/B STAT5 A/B STAT5 A/B STAT5 A/B Androgen-responsive element STAT5A/B binding GAS site

More Related